ALKS vs. MDGL, FOLD, IONS, GERN, AGIO, DVAX, LGND, PCRX, IRWD, and MNKD
Should you be buying Alkermes stock or one of its competitors? The main competitors of Alkermes include Madrigal Pharmaceuticals (MDGL), Amicus Therapeutics (FOLD), Ionis Pharmaceuticals (IONS), Geron (GERN), Agios Pharmaceuticals (AGIO), Dynavax Technologies (DVAX), Ligand Pharmaceuticals (LGND), Pacira BioSciences (PCRX), Ironwood Pharmaceuticals (IRWD), and MannKind (MNKD). These companies are all part of the "pharmaceutical preparations" industry.
Alkermes (NASDAQ:ALKS) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, community ranking, profitability and media sentiment.
95.2% of Alkermes shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 4.8% of Alkermes shares are held by insiders. Comparatively, 23.9% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Alkermes has a net margin of 25.17% compared to Madrigal Pharmaceuticals' net margin of 0.00%. Alkermes' return on equity of 20.31% beat Madrigal Pharmaceuticals' return on equity.
In the previous week, Alkermes had 18 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 24 mentions for Alkermes and 6 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.32 beat Alkermes' score of 0.09 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.
Alkermes has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.
Alkermes has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -0.33, meaning that its share price is 133% less volatile than the S&P 500.
Alkermes received 238 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. Likewise, 70.69% of users gave Alkermes an outperform vote while only 68.56% of users gave Madrigal Pharmaceuticals an outperform vote.
Alkermes currently has a consensus price target of $35.38, indicating a potential upside of 47.09%. Madrigal Pharmaceuticals has a consensus price target of $356.73, indicating a potential upside of 55.21%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than Alkermes.
Summary
Alkermes beats Madrigal Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Alkermes News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alkermes Competitors List
Related Companies and Tools
